Spotlight

Around the Practice

Between the Lines

Contemporary Concepts

Journal

OncView

Podcasts

Readout 360

2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates

CancerNetwork® Inaugural Face-Off

Contemporary Concepts in Hematologic Oncology

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Acute Myeloid Leukemia

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancer

Gynecologic Cancer

Hematology

Leukemia

Lung Cancer

Lymphoma

Pediatric Cancers

Skin Cancer

Clinical Topics

Integrative Care

Global Bulletin

All News

Approval Alert

2 Minute Drill

Around the Practice

Between the Lines

Clinical Consult

Expert Interviews

Face Off

Medical World News

Morning Rounds

OncView

Podcasts

Readout 360

Satellite Sessions

Emily A. Lemke, DNP, AGPCNP-BC, AOCNP

home / authors / emily-lemke-dnp-agpcnp-bc-aocnp

Articles

Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer

January 17th 2019

In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777